Laura Williams
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Laura Williams
Earlier roles on record: Board Member at Enliven Therapeutics, Inc. (ELVN) until February 23, 2023. Enliven Therapeutics, Inc. reported in an 8-K filed March 1, 2023 that Laura Williams resigned as Board, effective February 23, 2023. The proxy statement of Ardelyx, Inc. reports total compensation of $2,827,381 for Laura Williams in fiscal 2024, including a base salary of $522,720. Disclosed compensation is on record for 3 fiscal years. Laura Williams has spoken on 1 earnings call across 1 company, most recently for Ardelyx, Inc. on February 19, 2026.
“Pursuant to the Merger Agreement, on February 23, 2023, immediately prior to and effective upon the closing of the Merger, David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Ardelyx, Inc. (ARDX)
Proxy statement
CurrentStart not stated–present
-
Start not stated–2023-02-23
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Ardelyx, Inc.
Other people whose current roles at this company are on record from its filings.
- Michael Raab CEO, Board Member
- Keith Santorelli CFO
- Susan Hohenleitner CFO
- Joseph Reilly Chief Accounting Officer
- Justin Renz Chief Accounting Officer
- Robert Felsch Chief Accounting Officer
- David Mott Board Member
- Merdad Parsey, M.D., Ph.D Board Member
- Muna Bhanji Board Member
- Muna Bhanji, R.Ph Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Ardelyx, Inc. (ARDX) | M.D., M.P.H. Chief Medical Officer | $522,720 | $2,827,381 |
| 2023 | Ardelyx, Inc. (ARDX) | M.D., M.P.H. Chief Medical Officer | $483,600 | $1,627,431 |
| 2022 | Ardelyx, Inc. (ARDX) | M.D., M.P.H. Chief Medical Officer | $465,000 | $1,055,211 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.